Organon & Co. (NYSE:OGN) Upgraded at Zacks Research

Zacks Research upgraded shares of Organon & Co. (NYSE:OGN) from a strong sell rating to a hold rating in a research report released on Tuesday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Barclays lifted their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, Organon & Co. has an average rating of “Reduce” and a consensus price target of $8.50.

Organon & Co. Stock Up 1.1%

OGN opened at $9.32 on Tuesday. The business has a 50 day moving average price of $7.00 and a 200 day moving average price of $7.73. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.24. The company has a debt-to-equity ratio of 11.47, a quick ratio of 1.23 and a current ratio of 1.82. The firm has a market cap of $2.42 billion, a P/E ratio of 13.12, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The company had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.52 billion. During the same quarter last year, the business earned $0.90 EPS. The company’s revenue for the quarter was down 5.3% on a year-over-year basis. Research analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd were issued a dividend of $0.02 per share. The ex-dividend date was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.9%. Organon & Co.’s payout ratio is 11.27%.

Institutional Investors Weigh In On Organon & Co.

Hedge funds have recently modified their holdings of the business. Foster Dykema Cabot & Partners LLC bought a new position in Organon & Co. during the third quarter worth $29,000. Farther Finance Advisors LLC boosted its holdings in Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after purchasing an additional 2,033 shares during the period. Rothschild Investment LLC grew its position in Organon & Co. by 73.1% in the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after purchasing an additional 1,646 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in Organon & Co. in the 4th quarter worth $44,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Organon & Co. during the 4th quarter worth about $47,000. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.